Mifepristone Patent Expiration
Mifepristone is used for managing symptoms associated with Cushing's syndrome. It was first introduced by Danco Laboratories Llc
Mifepristone Patents
Given below is the list of patents protecting Mifepristone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Korlym | US10231983 | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients | Aug 22, 2038 | Corcept Therap |
| Korlym | US10314850 | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients | Aug 22, 2038 | Corcept Therap |
| Korlym | US10780097 | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients | Aug 22, 2038 | Corcept Therap |
| Korlym | US10195214 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | Jun 19, 2037 | Corcept Therap |
| Korlym | US10842800 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | Jun 19, 2037 | Corcept Therap |
| Korlym | US11969435 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | Jun 19, 2037 | Corcept Therap |
| Korlym | US12097210 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | Jun 19, 2037 | Corcept Therap |
| Korlym | US10151763 | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | Jan 18, 2037 | Corcept Therap |
| Korlym | US9829495 | Method for differentially diagnosing ACTH-dependent Cushing's syndrome | Aug 15, 2036 | Corcept Therap |
| Korlym | US10006924 | Method for differentially diagnosing ACTH-dependent cushing's syndrome | Aug 12, 2036 | Corcept Therap |
| Korlym | US10495650 | Method for differentially diagnosing ACTH-dependent Cushing's syndrome | Aug 12, 2036 | Corcept Therap |
| Korlym | US10166242 | Optimizing mifepristone levels for Cushing's patients | Apr 20, 2036 | Corcept Therap |
| Korlym | US10166243 | Optimizing mifepristone levels for cushing'S patients | Apr 20, 2036 | Corcept Therap |
| Korlym | US10660904 | Optimizing mifepristone levels for cushing's patients | Apr 20, 2036 | Corcept Therap |
| Korlym | US9943526 | Optimizing mifepristone levels for cushing's patients | Apr 20, 2036 | Corcept Therap |
| Korlym | US10500216 | Optimizing mifepristone absorption | Mar 05, 2033 | Corcept Therap |
| Korlym | US10842801 | Optimizing mifepristone absorption | Nov 15, 2032 | Corcept Therap |
| Korlym | US8921348 | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists | Aug 27, 2028 | Corcept Therap |
Mifepristone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Mifepristone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| PT150 Drug for Use in Alcohol Use Disorder | Pop Test Oncology LLC | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Mifepristone Outpatient Labour Induction | Chelsea and Westminster NHS Foundation Trust | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset | Nova Southeastern University | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1 |
| Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive | Leiden University Medical Center | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Comparison of Efficacy and Safety of Oral Versus Vaginal Misoprostol in Missed Abortion in First Trimester of Pregnancy | Hamna Khaliq | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE1 |